Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation

Cited by (1,000)

Items 701–800 of 1,000

1. Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
   Patrícia O. Guimarães, Renato D. Lópes, Daniel M. Wojdyla, John Hunter Alexander, Shaun G. Goodman, Ronald Aronson, Sigrun Halvorsen, Peter Sinnaeve, Dragoş Vinereanu, Robert F. Storey et al. · 2024 · The American Journal of Medicine
2. Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
   Marat Fudim, Renato D. Lópes, DANIEL M. WOJDYLA, Roxana Mehran, Muhammad Shahzeb Khan, Christopher Bull Granger, Shaun G. Goodman, Ronald Aronson, Stephan Windecker, John Hunter Alexander · 2025 · JACC Advances
3. Selección de lo mejor del año 2019 en arritmias y estimulación cardiaca
   Eduardo Arana‐Rueda, Manuel Frutos, Federico Gómez‐Pulido, Juan Manuel Durán-Guerrero, Juan Antonio Sánchez-Brotons, Juan Acosta, Álvaro Arce‐León, Alonso A. Pedrote · 2019 · REC CardioClinics
4. Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
   Despoina-Rafailia Benetou, Charalampos Varlamos, Aikaterini Mpahara, Dimitrios K. Alexopoulos · 2020 · American Journal of Cardiovascular Drugs
5. Current and Emerging Therapies for Atherosclerosis
   Adam J. Nelson, Stephen James Nicholls · 2020 · Springer eBooks
6. Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study
   N. A. Sycheva, L. Yu. Koroleva, В. П. Носов, Г. В. Ковалева, N. N. Paikova, A. T. Volkova, A. M. Kisel · 2020 · Kardiologiia
7. Defining the HBR patient – another step in the right direction
   Róisín Colleran, Philip M. Urban · 2020 · EuroIntervention
8. Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
   Anton Camaj, Michael S. Miller, Jonathan L. Halperin, Gennaro Giustino · 2020 · Cardiology Clinics
9. Para uma vinda bem-vinda: A visita à maternidade como uma prática humanizada no Sistema Único de Saúde (SUS)
   Jaqueline Batista de Oliveira Costa, Milena Ramos Alcântara, Débora Vieira dos Santos, Débora Cândido de Souza · 2021 · Editora Poisson eBooks
10. Missed Opportunities to Initiate Oral Anticoagulant in Atrial Fibrillation: Insights from Australian Acute Coronary Syndrome Registries
    Miles Ma, Karice K. Hyun, Mario I D'Souza, Derek P. Chew, David B. Brieger · 2021 · Heart Lung and Circulation
11. Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT‐CVD) study
    Sanam Verma, Shaun G. Goodman, Mary Tan, Benoit Daneault, Bruce J. Lubelsky, Samer Mansour, Andy Lam, David J. Laflamme, Wayne J. Tymchak, Robert C. Welsh et al. · 2021 · International Journal of Clinical Practice
12. Do non-vitamin K antagonist oral anticoagulants increase the risk of myocardial infarction?
    Stefan Grajek, Marta Kałużna-Oleksy · 2022 · Kardiologia Polska
13. Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus
    Minerva Codruța Bădescu, Victorița Șorodoc, Cătălina Lionte, Anca Ouatu, Raluca Ecaterina Haliga, Alexandru Dan Costache, Oana Nicoleta Buliga-Finiș, Ioan Şimon, Laurențiu Șorodoc, Irina Iuliana Costache et al. · 2023 · Journal of Personalized Medicine
14. Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention
    Рягина Вероника Анатольевна, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova · 2023 · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
15. Managing Patients With Concurrent High Risk for Bleeding and Thromboembolic Events
    Roland Fejes, Tamás Szűcsborús, András Czombos, Csaba Góg, Zoltán Ruzsa · 2024 · Cureus
16. Exploring the Perioperative Use of DOACs, off the Beaten Track
    Fabiana Lucà, Fabrizio Giovanni Oliva, Simona Giubilato, Maurizio Giuseppe Abrignani, Carmelo Massimiliano Rao, Stefano Cornara, Giorgio Caretta, Stefania Angela Di Fusco, Roberto Ceravolo, Iris Parrini et al. · 2024 · Journal of Clinical Medicine
17. Practical Prescribing: Direct oral anticoagulants
    Roy Khalifé, Allison Burnett, Tobias Tritschler, Beth Waldron, Yan Xu · 2024 · BMJ
18. Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy?
    Bernhard Wernly, Michael Lichtenauer, David Erlinge, Christian Jung · 2019 · Clinical Research in Cardiology
19. Current status of percutaneous coronary intervention in patients with atrial fibrillation: The Fushimi AF Registry
    Mitsuru Abe, Nobutoyo Masunaga, Mitsuru Ishii, Kosuke Doi, Kenjiro Ishigami, Syuhei Ikeda, Yuya Aono, Yoshimori An, Moritake Iguchi, Masahiro Esato et al. · 2019 · Journal of Cardiology
20. Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board
    Bart A. Mulder, Jurriën M. ten Berg, Hugo Ten Cate, Nick van Es, Martin E W Hemels, Laurens Jaap Kappelle, H. B. Bearda Bakker, Gert Jan de Borst, Derk J. Drenth, Geert‐Jan Geersing et al. · 2020 · Netherlands Heart Journal
21. Therapeutic Monitoring of Direct Oral Anticoagulants—Back to the Future?
    Kai Hu, Georg Ertl, Peter Nordbeck · 2020 · Journal of Cardiovascular Pharmacology
22. Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model
    Daisuke Kitano, Suguru Migita, Yuxin Li, Rie Takahashi, Yoshiki Taniguchi, Takafumi Kurosawa, Mitsumasa Sudo, Hironori Haruta, Takafumi Hiro, Tadateru Takayama et al. · 2020 · Journal of Atherosclerosis and Thrombosis
23. 2020 guidelines for the diagnosis and management of atrial fibrillation
    Belinda Linden · 2020 · British Journal of Cardiac Nursing
24. HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT
    Dagmara Wojtowicz, Anna Tomaszuk−Kazberuk, Jolanta Małyszko, Marek Koziński · 2020 · Wiadomości Lekarskie
25. Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
    Firas R. AL-Obaidi, Hayley Anne Hutchings, Andy S.C. Yong, Laith Alrubaiy, Hasan Ali Farhan, Mohammed H. Al-Ali, Tahsin Al-Kinani, M Almyahi, H Alkenzawi, Nazar Hassan Al-Sudani · 2021 · Current Cardiology Reviews
26. Dual Versus Triple Therapy in Patients with Acute Coronary Syndrome and an Anticoagulation Indication: A Systematic Review with Meta-Analysis and Trial-Sequential Analysis
    Rahul Gupta, Aaqib Habib Malik, Rajiv Gupta, Purva Ranchal, Srikanth Yandrapalli, Brijesh D. Patel, William H. Frishman, Wilbert S. Aronow, Jalaj Garg · 2021 · Cardiology in Review
27. Preliminary Study on the Safety and Efficacy of One-Stop Treatment of Percutaneous LAAO Combined with Coronary Intervention for Higher Risk of Bleeding in Patients with AF Complicated with CHD
    Xiaofei Jiang, Jie Zeng,, Lintao Zhong, Weimin Zhu, Jun Li · 2021 · The Heart Surgery Forum
28. Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study
    Felipe Homem Valle, Shaun G. Goodman, Mary Tan, Andrew C.T. Ha, Samer Mansour, Robert C. Welsh, Andrew Tze-Kay Yan, Kevin R. Bainey, Stéphane Rinfret, Brian James Potter et al. · 2021 · CJC Open
29. Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis
    Е. П. Панченко · 2021 · Aterotromboz = Atherothrombosis
30. Pharmacological Treatment of Tachyarrhythmias in Acute Myocardial Infarction - a Review
    Alexandru Ioan Deaconu, Silvia Deaconu, Andrei Radu, Maria Dorobanţu · 2021 · Romanian Journal of Cardiology
31. Effect of New Evidence on Antithrombotic Therapies in Atrial Fibrillation Patients Who Undergo Percutaneous Coronary Intervention in Alberta, Canada
    Theresa E. Eberhardt, Tammy J. Bungard, Michelle M. Graham, Michelle Picard, Grace T. Wang, Margaret L. Ackman · 2021 · CJC Open
32. Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial.
    Marat Fudim, DANIEL M. WOJDYLA, John Hunter Alexander, Shaun G. Goodman, Roxana Mehran, Stephan Windecker, RONALD S. ARONSON, Dragoş Vinereanu, Sigrun Halvorsen, Maria Cecilia Bahit et al. · 2021
33. Analysis of Cerebrovascular Events after Coil Embolization of Unruptured Cerebral Aneurysms in Patients Taking Anticoagulants
    Hayatsura Hanada, Kouhei Nii, Kimiya Sakamoto, Ritsurou Inoue, Yoko Hirata, Kodai Matsuda, Jun Tsugawa, Sho Takeshita, Sachiko Shirakawa, Toshio Higashi · 2023 · Journal of Neuroendovascular Therapy
34. Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
    Martina Berteotti, Anna Maria Gori, Betti Giusti, Alberto Fortini, Guido Grossi, Niccolò Ciardetti, Angela Migliorini, Elena Lotti, Renato Valenti, Carlo Di Mario et al. · 2023 · Journal of Thrombosis and Thrombolysis
35. Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new‐generation drug‐eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)‐4 trial
    Xiaoxuan Gong, Rui Hua, Jianling Bai, Tianyu Wu, Qin Wang, Jinhua Zhang, Wenhao Zhang, Lianghong Ying, Yongsheng Ke, Xiaoyan Wang et al. · 2023 · Clinical Cardiology
36. Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome
    Rasha Kaddoura, Bassant Orabi, Mohamed A. Yassin, Amr Salah Omar · 2023 · Reviews in Cardiovascular Medicine
37. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation
    Mark Anthony Sammut, Dwayne Conway, Javaid Iqbal, Arvindra Krishnamurthy, Kenneth P. Morgan, Paul Morris, James D. Richardson, Alexander M.K. Rothman, Julian P. Gunn, Robert F. Storey · 2024 · Expert Review of Cardiovascular Therapy
38. Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy
    Muhammad Bilal Munir, Khansa Osman, Maryam Saleem, Kinjan Patel, Sudarshan Balla · 2019 · Cureus
39. Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
    Abdelmoniem Moustafa, Mohammad Ruzieh, Ehab Ahmed Eltahawy, Saima Karim · 2019 · Avicenna Journal of Medicine
40. Der zweite Blick: praktische diagnostische und therapeutische Checks in der rehabilitativen Neurologie
    Stefan Knecht, Tobias Schmidt‐Wilcke · 2020 · Der Nervenarzt
41. Optimal Antithrombotic Therapy in Patients with Atrial Fibrillation During Percutaneous Coronary Intervention
    О. Л. Барбараш, Kemerovo, Russian Federation, V.V. Kashtalap · 2020 · Doctor Ru
42. Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention
    Jiesuck Park, Eue‐Keun Choi, Kyungdo Han, Bongseong Kim, You‐Jung Choi, So‐Ryoung Lee, Jeehoon Kang, Myung‐Jin Cha, Kyung Woo Park, Seil Oh et al. · 2020 · PLoS ONE
43. Antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention: what has changed in the guidelines in 2020?
    Е. П. Панченко · 2020 · Aterotromboz = Atherothrombosis
44. An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs)
    Özgür Karcıoğlu, Sarper Yılmaz, Göksu Afacan, Eylem Ersan, Derya Abuşka, Sehmus Zengin, Bilgen Özkaya, Mandana Hosseinzadeh, Selman Yeniocak · 2021 · Cardiovascular & Hematological Agents in Medicinal Chemistry
45. Duale Thrombozytenhemmung nach akutem Koronarsyndrom oder perkutaner Koronarintervention – womit und wie lange?
    Harald Darius · 2021 · Der Internist
46. Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease
    Samer Al Said, Michael Ellscheid, Eleftherios T. Beltsios, Norbert Frey · 2021 · Hämostaseologie
47. Anticoagulants in the Management of Pulmonary Embolism
    Ladan Panahi, George Udeani, Michael A. Horseman, Jaye S. Weston, Nephy G. Samuel, Merlyn Joseph, Andrea Mora, Daniela Z. Bazan, Pooja H. Patel · 2021 · IntechOpen eBooks
48. Monotherapy with P2Y12 receptor inhibitors in patients treated by percutaneous coronary intervention
    Luiz Fernando Tanajura, Aurea Jacob Chaves, Andrea Sousa Abizaid, J. Ribamar Costa · 2021 · Journal of Transcatheter Interventions
49. Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome
    Abi Selvarajah, Anne H. Tavenier, Enrico Fabris, Maarten A.H. van Leeuwen, Renicus Suffridus Hermanides · 2022 · Journal of Clinical Medicine
50. Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation
    Carlos Escobar-Cervantes, Pablo Díez‐Villanueva, Clara Bonanad Lozano, Antonio Pose Reino, Manuel Almendro‐Delia, Lorenzo Fácila, Alfonso Valle, Carmen Suárez · 2023 · Expert Review of Cardiovascular Therapy
51. Ischaemic and bleeding risk assessment after myocardial infarction: combination is the key
    Arthur Darmon, Grégory Ducrocq · 2019 · Heart
52. After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
    Andrea Rubboli, Matteo Lisi · 2019 · Cardiovascular Drugs and Therapy
53. Atrial Fibrillation and Percutaneous Coronary Intervention
    Frederik Dalgaard, W. Schuyler Jones, Jonathan Paul Piccini · 2019 · Circulation Cardiovascular Interventions
54. No free lunch—the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI
    Marco Valgimigli, Felice Gragnano · 2020 · Annals of Translational Medicine
55. Combined Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Navigating Between Scylla and Charybdis
    John U. Doherty · 2020 · Annals of Internal Medicine
56. How Un-POPular Is Bleeding in Patients with TAVI?
    Frederick Feit · 2020 · New England Journal of Medicine
57. Antithrombotic therapy: less is more or the more the better?
    Carlo Andrea Pivato, Alberto Margonato, Cosmo Godino · 2020 · EP Europace
58. Patients With Atrial Fibrillation and PCI or ACS
    Pascal Vranckx, Dominick Joseph Angiolillo, Marco Valgimigli · 2022 · Journal of the American College of Cardiology
59. Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
    Roxana Mehran, Birgit Vogel, Pierre Levy · 2020 · Journal of Cardiology
60. Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation
    Despoina-Rafailia Benetou, Panayotis K. Vlachakis, Charalampos Varlamos, Dimitrios K. Alexopoulos · 2021 · US Cardiology Review
61. Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report
    Hamid Mahmood, Farhan Shahid, Mohaned Egred, Mohamed Farag · 2022 · European Heart Journal - Case Reports
62. A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
    Simona Giubilato, Fabiana Lucà, Andrea Pozzi, Giorgio Caretta, Stefano Cornara, Anna Pilleri, Concetta Di Nora, Francesco Amico, Irene Di Matteo, Silvia Favilli et al. · 2022 · Journal of Clinical Medicine
63. Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction!
    Pascal Vranckx, Marco Valgimigli · 2022 · EuroIntervention
64. Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens
    Maya R. Chilbert, Ashley E. Woodruff, Marissa Saber, Pavel Goriacko, Mark J Sinnett, David M. Jacobs · 2023 · Blood Coagulation & Fibrinolysis
65. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
    Alexander C. Fanaroff, Amit N. Vora, DANIEL M. WOJDYLA, Roxana Mehran, Christopher Bull Granger, Shaun G. Goodman, RONALD S. ARONSON, Stephan Windecker, John Hunter Alexander, Renato D. Lópes · 2024 · American Heart Journal
66. How Would You Manage This Patient With Recent-Onset Atrial Fibrillation? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
    Gerald W. Smetana, Eli V. Gelfand, Patricia Tung, Risa Beth Burns · 2025 · Annals of Internal Medicine
67. A Pivotal Step Forward in ACS Evidence-Based Care: Implementing the New NHF/CSANZ 2025 Acute Coronary Syndrome Guideline
    Timothy Abrahams, Derek P. Chew · 2025 · Heart Lung and Circulation
68. Dual Therapy Versus Triple Therapy Major Bleeding Outcomes in Patients With Atrial Fibrillation Who Developed Indications for Percutaneous Coronary Intervention: A Meta-Analysis
    Mary Martinae Lim Miro, Jonald O Lucero · 2025 · Philippine journal of cardiology.
69. Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol)
    Seyed Alireza Mirhosseini, Mohammad Reza Akbari, Davar Aldavood, Hooyar Zarifkar, Armin Attar, Javad Kojuri · 2025 · PLoS ONE
70. Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System
    Kannan Sridharan, Gowri Sivaramakrishnan · 2025 · Journal of Clinical Medicine
71. Personalized management and decision-making for non-ST-segment elevation acute coronary syndrome in vulnerable populations
    Pablo Díez‐Villanueva, César Jiménez-Méndez, Pedro Luis Cepas Guillén, Lidia Vilches, Fernando Rivero, Héctor García‐Pardo, Juan Manuel Sanchis, Albert Ariza‐Solé, Fernándo Alfonso · 2025 · Expert Review of Cardiovascular Therapy
72. Safety and optimal use of direct oral anticoagulant therapy
    Claudio Laudani, Luis Ortega‐Paz, Ali Zgheib, Georges El Khoury, Mohmmad M. Alawajneh, Maryam Farahmandsadr, Davide Capodanno, Dominick Joseph Angiolillo · 2025 · Expert Opinion on Drug Safety
73. Medications for anti-coagulation in stroke prevention
    Sachin Nayyar, Patrick Andrew Brown · 2025 · Elsevier eBooks
74. Umbrella review of anticoagulation strategies for secondary prevention of cardioembolic stroke in atrial fibrillation: efficacy, safety, and knowledge gaps
    Nicholas Aderinto, Israel Charles Abraham, Ahmedyar Hasan, Abieyuwa Tari-Ere Oshodin, Obianuju Iheomamere Muoghallu, Ebube Christopher Mbah, Florence Oluwatoyin Akintepede, Aderinola Halimat Abioye, Sulaiman Olaide Bukky, Morounfoluwa Patience Olalusi et al. · 2025 · Annals of Medicine and Surgery
75. Oral anticoagulant therapy and outcomes in new-onset atrial fibrillation during acute myocardial infarction: A systematic review and meta-analysis
    Kristina Gennadievna Pereverzeva, Ayoub Glenza, Sergey S Yakushin · 2026 · World Journal of Cardiology
76. Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
    Fengjiao Kang, Yin Wang, Fu-Hong Cai, Liuyun Wu, Lizhu Han, Qinan Yin, Yuan Bian · 2026 · PLoS ONE
77. Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs
    Maggie M. He, Joseph Magdy, Maryam Aziz, Jun Tan, Arka Das, Stephen Bentley Wheatcroft, Heerajnarain Bulluck · 2026 · Journal of Clinical Medicine
78. Safety and efficacy of DOACs in clinically complex phenotypes of patients with atrial fibrillation: focus on frailty, multimorbidity and polypharmacy
    Panteleimon Ε. Papakonstantinou, Gregory Y.H. Lip · 2026 · Expert Opinion on Drug Safety
79. Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail Population
    Lorenzo Scalia, Laura Gatto, Federica Giuseppa Agnello, Dario Calderone, Mihail Celeski, Antonio Popolo Rubbio, Francesco Prati, Luca Testa, Davide Capodanno, Marco Barbanti · 2026 · The American Journal of Cardiology
80. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial
    Yohei Sotomi, Ken Kozuma, Yoshiharu Higuchi, Gaku Nakazawa, Yoshihiro Morino, Kenji Ando, Junya Ako, Kengo Tanabe, Takashi Muramatsu, Ken Kobayashi et al. · 2026 · The Lancet
81. Cocaine-Provoked Pulmonary Vein Thrombosis
    Hardik Patel, Greg Flaker · 2026 · JACC Case Reports
82. 2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical Settings
    You Mi Hwang, Hong Euy Lim, Dae In Lee, Hee Tae Yu, Yae Min Park, Boyoung Joung · 2021 · Korean Journal of Medicine
83. Choice and Timing of Antithrombotic after Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis
    Dylan Ryan, Tarun Girotra, Wuwei Feng · 2023 · CNS & Neurological Disorders - Drug Targets
84. Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review
    Ian Michael Lancaster, Vikas S. Sethi, Deep Patel, Cyrus Tamboli, Elizabeth Pacer, Jeffrey Steinhoff, Meir Mizrahi, Andrew Willinger · 2023 · Cardiology in Review
85. Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens
    Julia Martínez-Sánchez, Leticia Castrillo, Dídac Jerez, Sergi Torramadé‐Moix, Marta Palomo, Guiomar Mendieta, Mohammad Urooj Zafar, Ana Belén Moreno‐Castaño, Pablo Sánchez, Juan J. Badimón et al. · 2023 · Scientific Reports
86. Regulation of Platelet Activation and Coagulation
    Tobias Harm, Karin Anne Lydia Mueller, Tobias Geisler · 2024 · Interventional Cardiology Clinics
87. Efficacy and safety of different oral anticoagulants for stroke prevention in older patients with atrial fibrillation: A network meta-analysis
    Han Zhang, Feng Liu, Xueli Lu · 2024 · Medicine
88. Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?
    Marufur Rahman, Vidun Wedagedera, William A. Parker, Robert F. Storey · 2025 · Expert Opinion on Pharmacotherapy
89. Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and acute myocardial infarction: a systematic review and meta-analysis
    Yi Zheng, Xinyu Zheng, George Bazoukis, Gary Tse, Tong Liu · 2025 · Postgraduate Medical Journal
90. Antithrombotische Therapie
    Bernd Mühlbauer, Hans Wille · 2025 · Springer eBooks
91. Antithrombotic agents and effect on outcomes in ischemic stroke with atrial fibrillation and large artery atherosclerosis: a real-world study
    Jilu Chen, Jianhua Cheng, Qiang Ye, Yuntao Liu, Yanlei Zhang, Zheng Zhang · 2025 · Frontiers in Neurology
92. Inferior vena cava thrombosis associated with endovascular cooling catheters: impact on clinical outcomes
    Morgane Laverdure, Derek Y F So, Aun‐Yeong Chong, ALEXANDER J. DICK, Michael P.V. Froeschl, Christopher A. Glover, Marino X. Labinaz, George A. Wells, Jordan Bernick, Michel R. Le May · 2025 · Resuscitation
93. Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention
    Diona Gjermeni, H Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk et al. · 2025 · Journal of Cardiovascular Translational Research
94. Controversies in Antithrombotic Therapy for Patients With Coronary Artery Disease and Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Literature Review
    Omar Almur, Baraa Emran, Fathi S Milhem, Qutayba Z. Ayaseh, Abdelfattah M. Dahmas, Maram M. Abukhalil, Sakeena Saife, Mohammad Bdair, Ayesha Younas, Haroun Neiroukh et al. · 2025 · Clinical Medicine Insights Cardiology
95. Antiplatelet Therapy in Coronary Artery Disease
    Claudio Laudani, Davide Capodanno, Dominick Joseph Angiolillo · 2025 · Springer eBooks
96. Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI)
    Ming Liang, Jun Jin, Ruiping Zhao, Hui Li, Shao‐Liang Chen, Limin Liu, Ping Xu, Wei Wang, Xiang Chao Cheng, Xuezhi Chen et al. · 2025 · BMC Medicine
97. Percutaneous coronary intervention in high-bleeding risk patients: a review of contemporary management strategies
    G. OVIEBO ANDO, Giulia Cavolina, Alessio Villari, Giulia Alagna, Francesca Campanella, Giovanni Taverna, Pierre François Sabouret, Piera Capranzano · 2026 · Expert Review of Cardiovascular Therapy
98. Is Aspirin Still Indispensable After PCI—Rethinking Dual Antiplatelet Therapy in Contemporary Practice
    Kartik Yadav, Sama Ehab Salah Ahmed, Mohamed Abdelgader, Roann Khalid, Murugapathy Veerasamy, Arka Das, Heerajnarain Bulluck · 2026 · Journal of Cardiovascular Development and Disease
99. The evolution of dual antiplatelet therapy in patients with coronary artery disease
    Moa Simonsson, Stefan Karl James, Jurriën M. ten Berg, Bruna Gigante · 2026 · European Heart Journal Open
100. Aspirin Withdrawal in Patients With Coronary Artery Disease
     Mattía Galli, Davide Capodanno, Jurriën M. ten Berg, Larisa H. Cavallari, Sunil V. Rao, Pedro A. Lemos, Marco Valgimigli, Mario F.L. Gaudino, Adnan Kastrati, Philippe Gabríel Steg et al. · 2026 · Journal of the American College of Cardiology